Value of Tc99m (V) Dmsa Compared to Tc99m Mibi in Evaluation of Bone and Bone Marrow Lesions in Patients with Multiple Myeloma.

Shahenda S. Salem¹ and Muhammed I. Ibrahim².

¹Nuclear Medicine department, Cairo University, Cairo, Egypt., ²Clinical hematology department, Mansoura University, Mansoura, Egypt.

Introduction: Multiple myeloma (MM) is primarily bone marrow neoplasm. Tc99m sestamibi (MIBI) is a potential imaging tracer in patients with multiple myeloma. Tc99m Pentavalent dimercaptosuccinic acid (V-DMSA) has an implication in imaging medullary carcinoma, head and neck tumors and soft tissue and bone tumors. Few reports evaluated imaging of multiple myeloma by Tc99m (V) DMSA and only one of them compared Tc99m (V) DMSA with Tc99m MIBI in assessment of chemotherapy effectiveness.

Objective: Is to compare value of Tc99m (V) DMSA and Tc99m MIBI in detection of bone and bone marrow lesions in patients with multiple myeloma.

Materials and Methods: 32 patients with MM (18 M and 14 F, mean age 55±9 years) were enrolled in this study. Tc99m MIBI scan was done first followed 48 hours later by Tc99m (V) DMSA scan. Whole body Tc99m MIBI scan was obtained 10 minutes after IV injection of 555 MBq of tracer. Whole body Tc99m (V) DMSA scan was acquired 2 hours following IV injection of 740 MBq of tracer. Results: sensitivity, specificity, PPV, NPV and accuracy of Tc99m (V) DMSA was 93%, 100%, 100%, 67% and 94 % versus 71%, %100, 100%, 33% and 75% for Tc99m MIBI, respectively. Comparing pattern of bone and bone marrow involvement, it was focal in 18 (56%) patients, diffuse in 5 (16%) patients, diffuse and focal in 3 (9%) patients and normal in 6 (19%) patients in Tc99m (V) DMSA scans, while, it was focal in 6 (19%) patients, diffuse in 11 (34%) patients, focal and diffuse in 3 (9%) patients and normal in 12 (38%) patients in Tc99m MIBI scans.

Conclusion: Tc99m (V) DMSA is better than Tc99m MIBI in evaluation of bone and bone marrow in patients with MM. Tc99m (V) DMSA performed better in detection of focal lesions, whereas Tc99m MIBI was superior in visualization of diffuse disease.

Key words: Multiple myeloma, Tc99m sestamibi, Tc99m Pentavalent dimercaptosuccinic acid, bone and bone marrow involvement.

Corresponding Author: Dr. Shahenda S. Salem  Email: afssalem@yahoo.com
scan may become a useful diagnostic tool in the
detection of osteolytic Tc99m MDP negative bone
metastases8. However, a little data have been published
to compare between Tc99m (V) DMSA and Tc99m
MIBI in detection of bone and bone marrow lesions in
multiple myeloma.

Objective: Is to evaluate compare Tc99m (V)
DMSA with Tc99m MIBI in the detection of bone
and bone marrow lesions in patients with multiple
myeloma.

MATERIALS AND METHODS

Thirty two consecutive patients with multiple
myeloma (18 males and 14 females, mean age 55±9
years) were referred to nuclear medicine department
(NEMROK), Cairo University and were prospectively
enrolled in the period from January, 2010 till June, 2010
in this study. Patient inclusion and research protocol was
approved by the ethical committee. All patients had an
informed consent before examinations.

Initial diagnosis and staging were made according
to standard criteria9. The patients were clinically and
biochemically evaluated at the time of the scan to
determine their clinical status and disease activity.
The patients were followed clinically after the scan for
at least 12 months with complete knowledge of their
laboratory and radiological follow up results.

Imaging Acquisition:
Tc99m MIBI Imaging: Tc99m MIBI scan was
acquired first in all patients followed 48 hours later by
Tc99m (V) DMSA scan to avoid carryover of image data.
Images were acquired on a dual head gamma camera
equipped with low energy general purpose collimator
(ADAC/PHILIPS Vertex plus) using a 20% window
centered at 140 Kev and coupled with a dedicated
computer system. Anterior and posterior whole body
scans were acquired for all patients to improve the
sensitivity of detecting small lesions.

Tc99m MIBI was prepared according to the
manufacturer’s instructions. Each patient received 555
MBq of Tc99m MIBI intravenously and anterior and
posterior whole body scan was obtained 10 minutes
after the injection10. The early scans were acquired at 10
minutes to avoid vertebral and pelvic shielding caused
by biliary excretion and over time decrease of tracer
bone uptake, which reported to occur in about half of
the patients, probably influenced by the mechanism of
active extrusion as well as over expression of
P-glycoprotein associated with multidrug resistance.

Tc99m (V) DMSA Imaging:
Tc99m (V) DMSA was prepared by adding 7%
sodium bicarbonate to the commercial DMSA kit.
Anterior and posterior whole body scans were acquired
2 hours following intravenous injection of 740 MBq of
the tracer. All scintigrams were obtained on the same
dual head gamma camera (ADAC/PHILIPS Vertex plus)
connected to low energy high resolution collimator using
a 20% window centered at 140 Kev and coupled with a
dedicated computer system11.

Imaging Interpretation:
Both sets of Tc99m (V) DMSA and Tc99m MIBI
scans were calcified into four classes:
1. Normal (only physiologic uptake i.e. the
nasopharynx, axial skeleton, breast, liver, spleen,
heart, kidneys, urinary bladder, great vessels and
skeletal muscles for Tc-99m V DMSA and in the
heart, liver and spleen for Tc99m MIBI).
2. Diffuse (diffuse bone marrow uptake in the axial
and appendicular skeleton).
3. Focal uptake (areas of focal uptake of the
radiotracer were seen).
4. Focal plus diffuse uptake (when both patterns
were evident)12.

The results of both sets of Tc99m (V) DMSA and
Tc99m MIBI scans for each patient were correlated
with a recent skeletal survey as a gold standard and
the biochemical and clinical data were also assessed to
detect disease activity.

Statistical Analysis:
Data were statistically analyzed using the SPSS
16 Software (SSPS incorporation, Chicago, USA).
Quantitative data were summarized and expressed
as mean±standard deviation, whereas qualitative
data were expressed as frequency. Sensitivity,
specificity, positive predictive value (PPV), Negative
Predictive Value (NPV) and accuracy of both studies
were calculated. Groups included in the study were
compared using the Kruskall–Wallis test and each of
the two groups was then compared using the Mann–
Whitney test. Significance was set at the value of less
than 0.05 level.

RESULTS

According to clinical staging of the patients; two
were at stage II and 30 were stage III (24 were IIIA
and 6 were IIIB). The mean time since the disease onset was 29.12±16.3 months. Fourteen patients were previously treated with radiochemotherapy and phosphate injections. Three patients were treated with radiochemotherapy, 9 patients were treated with chemotherapy and phosphate injection and 6 patients were treated with only chemotherapy. The patients were treated between 1 and 2 years before the study. The patients were referred to our center because of uncomplicated bony pains in fifteen patients (47%), bony pains with associated fracture in 2 patients (6%), bony pains with cord compression in 3 patients (9%) and bony pain and anemia in 3 patients (9%). Anemia was the sole presentation in 4 patients (13%), while hypercalcemia was the presentation in 5 patients (16%).

Of the 32 patients performed Tc99m (V) DMSA scans were positive in 26 patients and negative in 6 patients; 2 patients were false negative and 4 patients were true negative. While, Tc99m MIBI, 20 patients had positive scans and 12 patients had negative scans; 8 patients were false negative and 4 patients were true negative. No false positive results were found. No false positive results were also found (Table 1). The sensitivity, specificity, PPV, NPV and accuracy of Tc99m (V) DMSA was 93%, 100%, 100%, 67% and 94 % Versus 71%, %100, 100%, 33% and 75% for Tc99m MIBI, respectively (Table 2).

Comparing the pattern of bone and bone marrow uptake in both scans, it was focal in 18 (56%) patients, diffuse in 5 (16%) patients, diffuse+focal in 3 (9%) patients and normal in 6 (19%) patients in Tc99m (V) DMSA scans, while, it was focal in 6 (19%) patients, diffuse in 11 (34%) patients, diffuse+focal in 3 (9%) patients and normal in 12 (38%) patients in Tc99m MIBI scans (Table 3, Figure 1). Regarding the pattern of bone and bone marrow involvement in Tc99m (V) DMSA and Tc99m MIBI scans, a significant statistical difference between the 2 imaging methods was found, in particularly, Tc99m (V) DMSA detected focal pattern with higher frequency than Tc99m MIBI ($P < 0.001$). On the contrary, Tc99m MIBI detected diffuse pattern with a higher frequency than Tc99m (V) DMSA ($P < 0.001$).

Six patients with focal bone marrow involvement in Tc99m (V) DMSA showed diffuse activity in Tc99m MIBI scan. Both Tc99m (V) DMSA and the Tc99m MIBI scan revealed the same myelomatous infiltration pattern; normal in 6 patients, focal in 6 patients, diffuse in 5 patients and diffuse+focal in 3 patients. Finally 6 patients with focal pattern on Tc99m (V) DMSA were normal on Tc99m MIBI (Figure 2).

Correlating the results of both Tc99m (V) DMSA and Tc99m MIBI scans with disease activity of the patients; Tc99m MIBI showed positive uptake in 20 patients and were all positive in Tc99m (V) DMSA scan with evidence of active disease. Four of the 12 patients with a negative result on Tc99m MIBI scans were in remission and were also negative in Tc99m (V) DMSA scan. However, the other 8 patients had an active disease and 6 of them showed positive myelomatous bone marrow deposits on Tc99m (V) DMSA scan. While, the remaining two patients were negative Tc99m (V) DMSA scan in spite of disease activity.

Finally, Tc99m (V) DMSA upstaged and modified the clinical management in 6 patients (19%), found to be positive on Tc99m (V) DMSA and negative on Tc99m MIBI scans.

<table>
<thead>
<tr>
<th>Table 1: Results of Tc99m MIBI scan in comparison to skeletal X-ray survey in detecting bone lesions.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TP</strong></td>
</tr>
<tr>
<td>Tc99m (V) DMSA</td>
</tr>
<tr>
<td>Tc99m MIBI</td>
</tr>
<tr>
<td>TP: true positive, TN: true negative, FP: false positive, FN: false negative.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Table 2: Sensitivity, specificity, positive predictive value, negative predictive value and accuracy of Tc99m (V) DMSA scans compared to Tc99m MIBI scans in evaluation of bone lesions in patients with multiple myeloma.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Tc99m (V) DMSA</strong></td>
</tr>
<tr>
<td><strong>sensitivity</strong></td>
</tr>
<tr>
<td><strong>specificity</strong></td>
</tr>
<tr>
<td><strong>PPV</strong></td>
</tr>
<tr>
<td><strong>NPV</strong></td>
</tr>
<tr>
<td><strong>Accuracy</strong></td>
</tr>
<tr>
<td>PPV: positive predictive value, NPV: negative predictive value.</td>
</tr>
</tbody>
</table>
Table 3: Pattern of bone and bone marrow findings in both Tc99m (V) DMSA and Tc99m MIBI scans.

<table>
<thead>
<tr>
<th></th>
<th>N</th>
<th>F</th>
<th>D</th>
<th>F+D</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tc99m (V) DMSA</td>
<td>6 (19%)</td>
<td>18 (56%)</td>
<td>5 (16%)</td>
<td>3 (9%)</td>
</tr>
<tr>
<td>Tc99m MIBI</td>
<td>12 (38%)</td>
<td>6 (19%)</td>
<td>11 (34%)</td>
<td>3 (9%)</td>
</tr>
</tbody>
</table>


Figure 1 (A): 42 years old patient with previously treated multiple myeloma showing diffuse+focal pattern of uptake in both Tc99m MIBI and Tc99m (V) DMSA scans (a) Anterior and posterior whole body Tc99m MIBI scan shows diffuse marrow uptake with focal rib, vertebral and pelvic lesions [arrows].

Figure 1 (B): Anterior and posterior whole body Tc99m (V) DMSA scans show diffuse marrow uptake with focal rib, vertebral and pelvic lesions [arrows].

Figure 2 (A): 53 years old patient with previously treated multiple myeloma showing focal pattern on Tc99m (V) DMSA and normal on Tc99m MIBI scan (a): Anterior and posterior whole body Tc99m MIBI scan shows normal pattern of uptake.

Figure. 2 (B): Anterior and posterior whole body Tc99m (V) DMSA scans show multiple focal bone marrow lesions in multiple skull bones, ribs, right shoulder and multiple pelvic bones [arrows].

DISCUSSION

Conventional X-ray is the standard imaging technique in evaluation of patients with multiple myeloma. However, particularly in previously treated patients, X-ray has a serious limitation to identify bone lesions corresponding to sites no longer active because of successful therapy. Tc99m MDP is less sensitive than X-ray in detecting skeletal lesions in patients with MM as it is not capable of evaluating bone marrow disease activity owing to lack of osteoblastic response usually produced in bone. Tc99m
MIBI appeared to overcome this limitation, reliably detecting active bone lesions in MM patients. It also has been reported to be more specific than conventional X-ray in detection of active focal lesions in previously treated MM patients. In a prospective study by Alper et al. to determine the potential of Tc99m MIBI imaging for evaluation of extent of primary disease in 20 patients with advanced stage MM, compared with skeletal survey and bone scintigraphy. All Tc99m MIBI scans were positive for the presence of active MM, whereas skeletal surveys were positive in 18 patients (90%) with osteolytic lesions. Bone scintigraphy demonstrated MM in only 15 patients (75%)10.

Both Tc99m MIBI and Tc99m (V) DMSA have been reported as tumor imaging agents for many neoplasm and bone metastases including multiple myeloma11-13.

Tc99m MIBI accumulated in the viable tumor cells due to high cellularity and mitochondrial activation. Dimopoulos et al. reported localization of Tc99m MIBI inside the plasma cells infiltrating the bone marrow. Additionally, bone marrow biopsy showed linear correlation with bone marrow uptake of Tc99m MIBI14.

Tc99m (V) DMSA has a different mechanism of tumor accumulation than that of Tc99m MIBI. The high glycolytic rate of the malignant tissues results in increase in the production of lactic acid, hence the acidic pH of the tumor. Acidification of the tissues causes accumulation of Tc99m (V) DMSA15. Denoyer et al. recently reported that Tc99m (V) DMSA uptake in tumor cell lines is mediated by NaPi cotransporter type III16. Others demonstrated that Tc99m (V) DMSA is a marker of cell viability like 18F-fluorodeoxyglucose (FDG) and Tc99m MIBI, as detection of tumor viability is important in assessment of treatment efficacy17 as well as follow-up of cancer patients1.

The metabolic pathway of Tc99m (V) DMSA, which reflects the type III NaPi co-transporter activity is different from that of FDG, which follows the glucose transport and the glycolytic pathway. Therefore, Tc99m (V) DMSA could provide additional information on the metabolic status of tumors after treatment.

Some studies have suggested a potential role for MIBI scintigraphy during monitoring of cancer patients receiving and after chemotherapy18. However, Tc99m MIBI is also a probe of multidrug resistance (MDR) phenotype, which may interfere with determination of tumor activity19, 20. In their work, Denoyer, et al. demonstrated that Tc99m (V) DMSA was independent of chemoresistance mediated by the major efflux pumps expressed in cancer cells and by the high levels of P-glycoprotein and MRP1. The authors assumed that Tc99m (V) DMSA could provide further information on viability of tumors with MDR phenotype and Tc99m (V) DMSA could therefore be considered as a useful non-invasive tool for follow-up of resistant tumors21.

In the current study, we compared between Tc99m (V) DMSA and Tc99m MIBI in the evaluation of bone involvement in patients with multiple myeloma. Our findings showed that the sensitivity, specificity, PPV, NPV and accuracy for Tc99m (V) DMSA was 93%, 100%, 100%, 67% & 94 % compared to 71%, %100, 100%, 33% and 75% for Tc99m MIBI, respectively. These results showed a better sensitivity, NPV and accuracy for Tc99m (V) DMSA compared to Tc99m MIBI scan with the same specificity and PPV. Our results go hand in hand with a recent study published by Mele et al., who reported a sensitivity of 77 % for MIBI scan in a multicentre study evaluated 397 whole body scans done for patients with MM22. However, earlier studies reported higher sensitivity of MIBI ranged from 90 to 100 %, with the same specificity (88 to 96%)23-24. The intense hepatosplenic tracer uptake is possibly obscuring active and also small lesions in these localized areas. Finally, in Tc99m MIBI studies overexpression of P-glycoprotein associated with multidrug resistance could lower the lesion detection rate; hence its sensitivity as it has been shown that Tc99m MIBI is actively eliminated from the cell by P-glycoprotein.

Comparing the pattern of bone and bone marrow involvement on Tc99m (V) DMSA and Tc99m MIBI scans; Tc99m (V) DMSA detected focal lesions in higher frequency than Tc99m MIBI with a significant statistical difference between the 2 imaging methods (P < 0.001). On the contrary, Tc99m MIBI detected diffuse pattern in higher frequency than Tc99m (V) DMSA (P < 0.005).

In a study done by Fonti et al., Tc99m MIBI and MRI were found to be superior to FDG PET/CT for visualization of diffuse disease. Meanwhile, FDG PET/CT performed better than Tc99m MIBI and MRI in detection of focal lesions25.

Finally, Tc99m (V) DMSA upstaged and modified the clinical management in 6 patients (19%) by confirming osseous and bone marrow involvement in context of active disease.

**CONCLUSION**

Tc99m (V) DMSA is better than Tc99m MIBI in evaluation of bone and bone marrow lesions in patients with multiple myeloma and its uptake correlated with disease activity. Unlike Tc99m MIBI, Tc99m (V) DMSA is not affected by the MDR phenomenon; however, correlation with immunohistochemical analysis of P-glycoprotein in tumor cells is recommended. Tc99m
(V) DMSA performed better than Tc99m MIBI in the detection of focal lesions, whereas Tc99m MIBI was superior in the visualization of diffuse disease.

**REFERENCE**


